Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Recent work has indicated that the p160 SRC family of transcriptional co-activators are subject to amplification and overexpression in various human cancers. This Review discusses the molecular mechanisms responsible, along with the mechanisms by which SRCs promote breast and prostate cancer cell proliferation and survival.
The efficacy of endocrine therapies (such as tamoxifen) in breast cancer is limited by intrinsic and acquired therapeutic resistance. What do we know about the genetic lesions and molecular processes that determine endocrine resistance in the clinic, and how can we use this to improve therapy?
In recent years, there has been a tremendous advance in our understanding of the cellular functions of individual RecQ helicases. This Review discusses how these proteins might suppress genomic rearrangements, and therefore function as 'caretaker' tumour suppressors.
Death due to smoking — from cancer, vascular disease or tuberculosis — is growing worldwide, particularly in low- and middle-income countries, in which the prevalence of smoking is increasing. How many people could die from smoking before 2050 and how might this be avoided?
How does therapeutic resistance affect disease relapse? Here the authors argue that the tumour microenvironment mediates a complex form ofde novodrug resistance and that adjuvant inhibition of key stromal factors could prevent the emergence of therapeutic resistance and relapse.
The failure of three Phase III randomized trials that assessed the efficacy of anti-idiotype vaccines for the treatment of follicular lymphoma has raised many questions and controversies. In this article, Maurizio Bendandi expresses his thoughts on these findings and argues that new trials are necessary.
